Werewolf Therapeutics Q1 EPS $(0.39) Misses $(0.35) Estimate, Sales $742.00 Miss $1.82M Estimate
Portfolio Pulse from Benzinga Newsdesk
Werewolf Therapeutics (NASDAQ:HOWL) reported Q1 EPS of $(0.39), missing estimates by 11.43% and marking a 14.71% decrease from last year. Sales were $742.00, significantly below the $1.82M estimate, representing a 99.98% decrease from the previous year.
May 03, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Werewolf Therapeutics reported significantly lower than expected Q1 earnings and sales, missing analyst estimates.
The significant miss in both earnings per share and sales compared to analyst estimates, along with a substantial decrease from the previous year's figures, is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100